FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). PMID 42424047 · JAMA Oncol · 2026-Jul-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Secondary Prophylaxis of Recurrent Clostridioides difficile Infections During Systemic Antibiotics with Vancomycin (SPORES-V): study protocol for a randomized controlled trial. PMID 42421140 · Trials · 2026-Jul-09 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults ≥60 Years of Age. PMID 42419724 · J Infect Dis · 2026-Jul-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. PMID 42418775 · N Engl J Med · 2026-Jul-09 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. PMID 42418774 · N Engl J Med · 2026-Jul-09 This is a Phase III randomized trial of a drug (setmelanotide) for acquired hypothalamic obesity, not a malignant neoplasm. While it meets criteria for being human, randomized, Phase III, drug-intervention, and original-result, it is not oncology. Furthermore, the primary endpoint is mean percent change in BMI, which is not a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. PMID 42149993 · N Engl J Med · 2026-Jul-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. PMID 41812190 · N Engl J Med · 2026-Jul-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparing the Effectiveness and Safety of Different Third-Line Management Options for Patients with Metastatic Colorectal Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis. PMID 42512271 · Cancers (Basel) · 2026-Jul-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Perioperative Nivolumab and Ipilimumab with Chemotherapy and Chemoradiation for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: A Phase 1/2 Non-Randomized Clinical Trial. PMID 42512265 · Cancers (Basel) · 2026-Jul-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Zanidatamab vs trastuzumab with or without PD-1 blockade in HER2-positive metastatic gastric cancer: a reconstructed patient-level pooled analysis. PMID 42446122 · Oncologist · 2026-Jul-08 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 2 Panel · risk visible |
| Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. PMID 42424856 · Vaccine · 2026-Jul-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Robotic right hemicolectomy with intracorporeal anastomosis versus laparoscopic right hemicolectomy with extracorporeal anastomosis (PRORHEM): protocol for a randomized controlled trial. PMID 42420958 · BMC Surg · 2026-Jul-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD. PMID 42420599 · Breast Cancer Res Treat · 2026-Jul-08 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Rationale, design and methods of the Cul-CM study: a protocol for cultural adaptation of contingency management in adults with stimulant use disorder. PMID 42419893 · BMJ Open · 2026-Jul-08 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial. PMID 42419755 · Br J Haematol · 2026-Jul-08 The record is a randomized, drug-interventional trial with a primary time-to-event endpoint (PFS). However, it is a subgroup analysis of the main trial results, and the trial phase is not explicitly stated in the metadata. While it is likely a Phase III trial based on the cooperative group and randomization, the explicit phase cannot be established from the provided text. Therefore, is_eligible is set to null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study. PMID 42419338 · Lancet Haematol · 2026-Jul-08 The record describes a phase 1 expansion study, not a randomized Phase II/III or Phase III/IIIb trial, and does not report a primary or key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis. PMID 42419336 · Lancet Oncol · 2026-Jul-08 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. PMID 42419335 · Lancet Infect Dis · 2026-Jul-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Safety, and Mechanism of the Qi-Lian-Xiao-Pi Prescription (WW-1) for Chronic Atrophic Gastritis After Helicobacter Pylori Eradication: Protocol for a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. PMID 42418263 · JMIR Res Protoc · 2026-Jul-08 The record is a protocol for an ongoing trial of a traditional Chinese medicine for a precancerous lesion (chronic atrophic gastritis), not a human malignant neoplasm. It lacks a primary/key secondary time-to-event efficacy endpoint and does not report formal results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trial. PMID 42415611 · Kidney Res Clin Pract · 2026-Jul-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Subgroup Analysis of Pooled Phase 3 Efficacy Data from Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) including Participants with Uropathogens Not-Susceptible to Nitrofurantoin. PMID 42413960 · Clin Infect Dis · 2026-Jul-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial. PMID 42479626 · J Crohns Colitis · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Decoding Small Cell Lung Cancer: Molecular Subtypes, Surface Antigens, and the Target-Modality Problem. PMID 42449715 · Cancers (Basel) · 2026-Jul-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension study. PMID 42413781 · J Am Acad Dermatol · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Everolimus and de novo malignancies after liver transplantation: a Nationwide Emulated Trial Using Real-World Data. PMID 42413767 · JHEP Rep · 2026-Jul-07 The study is a non-randomized, observational analysis using an 'emulated target trial' framework. While it is oncological, involves humans, has a drug intervention, and reports time-to-event efficacy results, it fails the core requirement of being a randomized controlled trial and does not have an explicitly stated Phase III/IIIb or Phase II/III classification. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial. PMID 42413526 · Lancet Respir Med · 2026-Jul-07 The record describes a single-arm, Phase 1b/2 trial with a primary endpoint of ORR. It is not a randomized Phase III/IIIb or Phase II/III trial and lacks a time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC). PMID 42412689 · Future Oncol · 2026-Jul-07 The record describes a modeling and transportability analysis (a 'Targeted literature review' and 'Outcome regression models') using data from other trials (RATIONALE-315, RATIONALE-303, RATIONALE-312). It is not a primary, original result report of a Phase III randomized trial with a drug intervention and a time-to-event endpoint. The publication is a secondary analysis, likely a health-economic or modeling study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid. PMID 42333640 · J Am Heart Assoc · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen. PMID 42223961 · JAMA · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial. PMID 42153665 · Circulation · 2026-Jul-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intra-Arterial thrombolysis after SUCCESSful angiographic recanalization in acute large-vessel occlusion stroke of the anterior circulation (IA-SUCCESS): a multicentre, randomised, clinical trial protocol. PMID 42439416 · Eur Stroke J · 2026-Jul-06 方案论文未报告临床试验结果。 |
H
L
|
旧查询独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Adjuvant Interferon-β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study. PMID 42410902 · J Dermatol · 2026-Jul-06 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
|
仅历史库存 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Effect of endoscopic screening for non-cardia gastric cancer: a 12-year report of a population-based randomized trial. PMID 42410417 · BMC Med · 2026-Jul-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic versus open pancreaticoduodenectomy for non-pancreatic periampullary adenocarcinomas: study protocol for a multicentre randomised controlled trial in China. PMID 42409398 · BMJ Open · 2026-Jul-06 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Locoregional recurrence patterns and prognostic outcomes in early-stage natural killer/T-cell lymphoma treated with sandwich chemoradiotherapy: A post hoc analysis of a randomized controlled trial. PMID 42409316 · Pract Radiat Oncol · 2026-Jul-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Multi-Center Randomized Trial Evaluating the Safety and Effectiveness of the Instylla Hydrogel Embolic System (HES) for Vascular Occlusion of Hypervascular Tumors. PMID 42409306 · J Vasc Interv Radiol · 2026-Jul-06 The study is a randomized trial of a device (hydrogel embolic system) for tumor embolization. It does not involve a drug intervention and does not report a time-to-event efficacy endpoint; the primary endpoints are safety (Freedom from MAE) and technical success (effectiveness). It is therefore ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 study]. PMID 42409049 · Pneumologie · 2026-Jul-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. PMID 42407012 · J Clin Oncol · 2026-Jul-06 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Linzagolix versus leuprorelin in Japanese women with uterine leiomyomas: a phase 3, randomized, active-controlled, non-inferiority trial. PMID 42406777 · Hum Reprod · 2026-Jul-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study. PMID 42403263 · Diabetes Obes Metab · 2026-Jul-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial. PMID 42402625 · Signal Transduct Target Ther · 2026-Jul-06 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 3 Panel · risk unclear |
| Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study). PMID 41968990 · Jpn J Clin Oncol · 2026-Jul-06 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer. PMID 42427862 · Res Sq · 2026-Jul-05 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications. PMID 42402363 · Cancer Invest · 2026-Jul-05 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel, Multi-Centre, Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects with Moderate to Severe Submental Fat. PMID 42401423 · Aesthet Surg J · 2026-Jul-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial. PMID 42401951 · BMC Pharmacol Toxicol · 2026-Jul-04 The study is an original, randomized, oncology trial with a drug intervention, but the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. Furthermore, while a time-to-event measure (time-to-onset of neuropathy) is reported, it is a secondary endpoint related to toxicity, not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) required for inclusion in the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preoperative whey protein supplementation for postoperative nausea, vomiting and recovery in well-nourished gynecologic tumor patients: a randomized controlled trial. PMID 42401710 · Sci Rep · 2026-Jul-04 The study is a randomized trial in gynecologic oncology patients (human, oncology). It is an original primary result report. However, it is excluded because: 1) the primary endpoint is incidence of postoperative nausea and vomiting (PONV), a binary outcome, not a time-to-event endpoint (OS, PFS, DFS, etc.) with KM/HR; 2) the intervention is a nutritional supplement (whey protein), not a systemic drug (chemotherapy, targeted therapy, immunotherapy, etc.); 3) the trial phase is not specified, and it does not appear to be a definitive Phase III/IIIb trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Combined indwelling pleural catheter with thoracoscopic talc poudrage for malignant pleural effusion management: a randomized non-inferiority trial. PMID 42399890 · BMC Pulm Med · 2026-Jul-04 The study is a randomized trial in oncology (malignant pleural effusion) with original results, but it is not a Phase III/IIIb or Phase II/III trial (phase unclear from text, not explicitly stated as such), does not have a drug-containing intervention (comparing procedural techniques: IPC + TTP vs. TTP alone), and does not have a primary/key secondary time-to-event efficacy endpoint (primary endpoint is pleurodesis success rate at 12 weeks, a binary outcome, not time-to-event). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of opioid-free anesthesia on postoperative anxiety in patients undergoing modified radical mastectomy for breast cancer: a randomized controlled trial. PMID 42399751 · BMC Anesthesiol · 2026-Jul-04 The study is a randomized trial in breast cancer patients, but the intervention is a perioperative anesthetic regimen (opioid-free vs. opioid-based), not a systemic oncology drug treatment. The primary endpoint is a patient-reported anxiety score at 24 hours, not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the criteria for a drug intervention or a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. PMID 42251856 · Lancet · 2026-Jul-04 The study is a randomized, phase 3 trial of a drug-containing intervention (CagriSema) in humans, with original results. However, it is not an oncology study; it evaluates a treatment for type 2 diabetes, a non-malignant condition. The primary efficacy endpoint is mean HbA1c change, which is a continuous measure, not a time-to-event outcome. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |